Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan · Delayed Price · Currency is JPY 4,225.00
+5.00 (0.12%)
Feb 13, 2026, 3:30 PM JST
Kaken Pharmaceutical Revenue
Kaken Pharmaceutical had revenue of 18.26B JPY in the quarter ending December 31, 2025, a decrease of -25.82%. This brings the company's revenue in the last twelve months to 75.66B, down -18.95% year-over-year. In the fiscal year ending March 31, 2025, Kaken Pharmaceutical had annual revenue of 94.04B with 30.52% growth.
Revenue (ttm)
75.66B
Revenue Growth
-18.95%
P/S Ratio
2.11
Revenue / Employee
67.20M
Employees
1,126
Market Cap
159.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 94.04B | 21.99B | 30.52% |
| Mar 31, 2024 | 72.04B | -940.00M | -1.29% |
| Mar 31, 2023 | 72.98B | -3.05B | -4.01% |
| Mar 31, 2022 | 76.03B | 1.06B | 1.41% |
| Mar 31, 2021 | 74.98B | -14.25B | -15.97% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Toho Holdings | 1.53T |
| Towa Pharmaceutical | 266.67B |
| Sawai Group Holdings | 200.00B |
| Tsumura & Co. | 189.50B |
| Nippon Shinyaku | 166.05B |
| Hisamitsu Pharmaceutical Co. | 159.27B |
| KYORIN Pharmaceutical | 133.26B |
| Mochida Pharmaceutical | 111.92B |
Kaken Pharmaceutical News
- 11 months ago - Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
- 1 year ago - Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Benzinga